Sanara MedTech Investor Presentation Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the "Company," "Sanara," "we," "our" or "us"). All statements other than statements of historical fact contained herein are forward-looking statements. These statements may be identified by terms such as "aims," "anticipates," "believes," "c ...

Shares of Sanara MedTech ( SMTI ) have remained under pressure this year as strong growth and improving profitability in the Surgical segment have been outweighed by concerns related to the rising debt levelsAn individual investor primarily focused on undercovered companies, with more than 50 companies on my watchlist. My areas include technology, software, electronics and the energy transition. I have been investing my personal capital for over 7 years in a broad range of companies globally. Through my yea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-39678 SANARA MEDTECH INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employ ...

Sanara MedTech Inc. (SMTI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -32.26%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced a loss of $0.18, delivering a surprise of 5.26%.Over the last four quarters, the company has surp ...

Sanara MedTech (SMTI) Q1 2025 Earnings Call May 14, 2025 08:00 AM ET Company Participants Ron Nixon - CEO & Executive ChairmanSeth Yon - President of CommercialSam Muppalla - CEOElizabeth Taylor - CFOYi Chen - Managing Director, Equity ResearchMatthew Park - Equity Research Associate Operator Welcome to the Sonera MedTech First Quarter of twenty twenty five Earnings Conference Call. Please note that this conference call is being recorded and a replay will be available on the Investor Relations page of the c ...

Sanara MedTech (SMTI) Q1 2025 Earnings Call May 14, 2025 08:00 AM ET Speaker0 Welcome to the Sonera MedTech First Quarter of twenty twenty five Earnings Conference Call. Please note that this conference call is being recorded and a replay will be available on the Investor Relations page of the company's website shortly. The company issued its earnings release earlier today. Before we begin, I would like to remind everyone that certain statements on today's call include forward looking statements within the ...

FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) - Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the first quarter ended March 31, 2025. Exhibit 99.1 Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaud ...

Core Viewpoint - Sanara MedTech Inc. is set to present at the Planet MicroCap Showcase: VEGAS 2025, highlighting its focus on developing transformative medical technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical, chronic wound, and skincare markets [1] Company Overview - Sanara MedTech Inc. specializes in medical technology, focusing on the development and commercialization of innovative products to enhance clinical outcomes and lower healthcare expenditures [3] - The company markets and distributes a range of surgical, wound, and skincare products primarily in the North American advanced wound care and surgical tissue repair markets [3] - Key products include CellerateRX® Surgical Activated Collagen®, FORTIFY TRG® Tissue Repair Graft, and various advanced biologic products such as ACTIGEN® Verified Inductive Bone Matrix and BIASURGE® Advanced Surgical Solution [3] - Sanara also offers telemedicine services for wound care and dermatology consultations, aiming to improve patient outcomes while managing costs [3] Upcoming Presentation - Management will present to investors on April 23, 2025, at approximately 3:30 p.m. Pacific Time during the Planet MicroCap Showcase [1] - Presentation materials will be available on the company's investor relations website prior to the event, along with a live audio webcast and an archive for later access [2]

Sanara MedTech Inc. (SMTI) shares ended the last trading session 8.1% higher at $29.20. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 15.5% loss over the past four weeks.The upside can be attributed to relief-rally across global markets following the announcement of a 90-day pause on tariff hike by the United States.This company is expected to post quarterly loss of $0.31 per share in its upcoming report, which r ...

Business Segments and Strategy - The company operates through two reportable segments: Sanara Surgical and Tissue Health Plus (THP) to enhance resource allocation and management focus [20]. - Sanara Surgical segment includes products like CellerateRX Surgical and BIASURGE, with CellerateRX Surgical primarily used for surgical wound management and BIASURGE launched in November 2023 [21][28]. - THP aims to introduce a value-based wound care program targeting Medicare Advantage payers, expected to launch a pilot program in Q2 2025 [24][33]. - THP's contracts are anticipated to have three-to-five-year terms, incorporating value-based pricing methodologies to align with payer financial goals [34]. - The company established a joint venture, SI Healthcare Technologies, with InfuSystem to enhance wound care solutions and improve patient outcomes [37]. - The company seeks partnerships and acquisitions to enhance its product and service offerings, particularly in value-based care models [41][42]. - The company plans to expand its geographic footprint and deepen market penetration in the surgical, wound, and skincare markets [39]. - New innovative products are under development to improve surgical site outcomes and treat chronic wounds, focusing on efficacy and cost-effectiveness [40]. Market Opportunities - Approximately 15% of the Medicare beneficiary population has chronic nonhealing wounds, indicating a significant market opportunity for the company's products [49]. - Over 34 million people in the U.S., or about 10% of the population, suffer from diabetes, which is associated with poor wound healing and presents a substantial market for diabetic foot ulcer treatments [50]. - Venous leg ulcers affect approximately 600,000 people annually in the U.S., highlighting another critical area for the company's wound care solutions [51]. - The surgical and wound care markets are expected to grow due to demographic trends and increasing healthcare costs, with the company positioned to benefit from this growth [44]. Product Development and Innovation - The company has a robust pipeline of surgical, wound, and skincare products expected to be marketed soon, with a focus on statistically significant clinical and health economic outcomes data to drive adoption and lower costs for payors [47]. - The company has demonstrated a 59% reduction in surgical site infection rates when using CellerateRX Surgical collagen in elective multispecialty surgical procedures, with a 69% decrease in clean cases [55]. - The company has a pipeline of product candidates aimed at addressing opportunistic pathogens and wound healing, but successful commercialization is uncertain [127]. - Future success relies on the ability to educate healthcare practitioners on the benefits and proper use of the company's products, which is critical for market acceptance [129]. Regulatory Environment - Medical devices must obtain FDA marketing clearance through the 510(k) premarket notification process, de novo classification, or PMA process, unless exempt [71]. - Class II devices generally require a 510(k) premarket notification, while most Class I devices are exempt from this requirement [72]. - The FDA must classify a de novo classification request within 120 days, and manufacturers must propose special controls for Class II devices [73]. - Class III devices require PMA approval, which involves extensive data demonstrating safety and effectiveness, and the FDA has 180 days to review the application [74]. - Clinical trials are often required for PMAs and sometimes for 510(k) submissions, with significant risk devices needing an IDE application [75]. - The company is subject to various governmental regulations that could impact the commercialization of new products, including delays in FDA approvals [116]. - The company faces significant challenges in complying with FDA regulations and maintaining good manufacturing practices, which could jeopardize product commercialization [124]. - Regulatory compliance is costly and time-consuming, impacting the development and marketing of products [146]. Financial Performance and Risks - The company has incurred net losses in most years since 2004 and plans to continue significant investments in its THP operating segment, which will substantially increase operating expenses [102]. - The company faces challenges in predicting revenue growth, and a shortfall in forecasted revenues may harm operating results [99]. - The company has experienced fluctuations in revenue and operating results, making future revenue growth difficult to predict [104]. - The company’s indebtedness could adversely affect its financial condition and limit its ability to fund operations and growth [117]. - The company anticipates that economic conditions and changes in reimbursement rates could impact its ability to sell products [108]. - The company expects pricing pressures due to increasing efforts by payors to limit healthcare costs, which may affect profitability [166]. Compliance and Legal Issues - The company is subject to extensive healthcare fraud and abuse laws, and noncompliance could result in substantial penalties [169]. - The company must comply with HIPAA regulations, which impose strict privacy and security standards for protected health information [90]. - The company may face civil and criminal penalties for violations of HIPAA, with significant repercussions for breaches affecting more than 500 individuals [91]. - The company faces risks from potential litigation related to intellectual property rights, which could divert resources and impact operations [145]. Corporate Governance and Shareholder Matters - The company has provisions in its Certificate of Formation that may limit shareholder actions against directors for breaches of fiduciary duties [198]. - The company has anti-takeover provisions that could delay or discourage favorable takeover attempts [199]. - A significant percentage of voting stock is controlled by a few shareholders, which may lead to conflicts of interest and affect corporate governance [195]. - The company has not paid cash dividends and does not plan to in the near future, limiting returns for shareholders [194]. Cybersecurity and Technology - The company has invested in cybersecurity measures, including growing its internal technology team and obtaining cybersecurity insurance [207]. - The company has not experienced any material adverse effects from cybersecurity threats to date [209].